Siolta Therapeutics

Siolta Therapeutics is a private, clinical-stage microbiome company pioneering the development of next-generation live biotherapeutics. Its core asset is the Precision Symbiotics Platform™, which integrates clinical data, bioinformatics, and microbial science to design bacterial consortia for preventive medicine. The company's lead program, STMC-103H, has reported positive Phase 2 results for the prevention of atopic dermatitis in high-risk infants, positioning it as a potential first-in-class preventive therapy. Siolta is supported by multiple SBIR grants and is advancing a pipeline targeting atopic dermatitis, necrotizing enterocolitis, and recurrent bacterial vaginosis.

Precision Symbiotics Platform™: A proprietary platform combining clinical data, bioinformatics, and microbial science to rationally design synergistic bacterial consortia for therapeutic use. Includes in-house GMP manufacturing capabilities for anaerobic live biotherapeutics.

Siolta operates in the competitive but pioneering live biotherapeutic product (LBP) space. It competes with other microbiome-focused companies (e.g., Vedanta Biosciences, Seres Therapeutics) developing defined bacterial consortia, as well as large pharma partners. Its focus on preventive medicine in allergy and niche, high-unmet-need areas like NEC provides a differentiated strategic position.